We have developed a versatile method for generating tolerogenic antigen-presenting cells in vivo by delivering mRNA encoding PDL1 via lipid nanoparticles. These tolerogenic antigen-presenting ...

showed a 27% reduction in the risk of death versus placebo AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited ...

In the phase 3 PROpel trial (NCT03732820) patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib plus abiraterone in the first-line setting showed significantly ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Yago Nieto, Department of Stem Cell ...